Women, men, and rheumatoid arthritis: Analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study

Tuulikki Sokka*, Sergio Toloza, Maurizio Cutolo, Hannu Kautiainen, Heidi Makinen, Feride Gogus, Vlado Skakic, Humeira Badsha, Tõnu Peets, Asta Baranauskaite, Pál Géher, Ilona Újfalussy, Fotini N. Skopouli, Maria Mavrommati, Rieke Alten, Christof Pohl, Jean Sibilia, Andrea Stancati, Fausto Salaffi, Wojciech RomanowskiDanuta Zarowny-Wierzbinska, Dan Henrohn, Barry Bresnihan, Patricia Minnock, Lene Surland Knudsen, Johannes W.G. Jacobs, Jaime Calvo-Alen, Juris Lazovskis, Geraldo da Rocha Castelar Pinheiro, Dmitry Karateev, Daina Andersone, Sylejman Rexhepi, Yusuf Yazici, Theodore Pincus

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

209 Citations (Scopus)

Abstract

Introduction: Gender as a predictor of outcomes of rheumatoid arthritis (RA) has evoked considerable interest over the decades. Historically, there is no consensus whether RA is worse in females or males. Recent reports suggest that females are less likely than males to achieve remission. Therefore, we aimed to study possible associations of gender and disease activity, disease characteristics, and treatments of RA in a large multinational cross-sectional cohort of patients with RA called Quantitative Standard Monitoring of Patients with RA (QUEST-RA). Methods: The cohort includes clinical and questionnaire data from patients who were seen in usual care, including 6,004 patients at 70 sites in 25 countries as of April 2008. Gender differences were analyzed for American College of Rheumatology Core Data Set measures of disease activity, DAS28 (disease activity score using 28 joint counts), fatigue, the presence of rheumatoid factor, nodules and erosions, and the current use of prednisone, methotrexate, and biologic agents. Results: Women had poorer scores than men in all Core Data Set measures. The mean values for females and males were swollen joint count-28 (SJC28) of 4.5 versus 3.8, tender joint count-28 of 6.9 versus 5.4, erythrocyte sedimentation rate of 30 versus 26, Health Assessment Questionnaire of 1.1 versus 0.8, visual analog scales for physician global estimate of 3.0 versus 2.5, pain of 4.3 versus 3.6, patient global status of 4.2 versus 3.7, DAS28 of 4.3 versus 3.8, and fatigue of 4.6 versus 3.7 (P < 0.001). However, effect sizes were small-medium and smallest (0.13) for SJC28. Among patients who had no or minimal disease activity (0 to 1) on SJC28, women had statistically significantly higher mean values compared with men in all other disease activity measures (P < 0.001) and met DAS28 remission less often than men. Rheumatoid factor was equally prevalent among genders. Men had nodules more often than women. Women had erosions more often than men, but the statistical significance was marginal. Similar proportions of females and males were taking different therapies. Conclusions: In this large multinational cohort, RA disease activity measures appear to be worse in women than in men. However, most of the gender differences in RA disease activity may originate from the measures of disease activity rather than from RA disease activity itself.

Original languageEnglish
Article numberR7
JournalArthritis Research and Therapy
Volume11
Issue number1
DOIs
Publication statusPublished - 14 Jan 2009

Fingerprint

Dive into the research topics of 'Women, men, and rheumatoid arthritis: Analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study'. Together they form a unique fingerprint.

Cite this